{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:13Z","timestamp":1789609093755,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BioMarin International Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00354-8","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T12:11:43Z","timestamp":1651752703000},"page":"1071-1083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The European Lambert\u2013Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn P.","family":"Sieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendal","family":"Le Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Postila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"354_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mus.25520","volume":"56","author":"DC Abenroth","year":"2017","unstructured":"Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL. Lambert\u2013Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve. 2017;56:421\u20136.","journal-title":"Muscle Nerve"},{"key":"354_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJGM. Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098\u2013107.","journal-title":"Lancet Neurol"},{"key":"354_CR3","first-page":"e5450","volume":"11","author":"A Anwar","year":"2019","unstructured":"Anwar A, Saleem S, Ahmed MF, Ashraf S, Ashraf S. Recent advances and therapeutic options in Lambert\u2013Eaton myasthenic syndrome. Cureus. 2019;11:e5450.","journal-title":"Cureus"},{"key":"354_CR4","first-page":"973808","volume":"2011","author":"NE Gilhus","year":"2011","unstructured":"Gilhus NE. Lambert\u2013Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808.","journal-title":"Autoimmune Dis"},{"key":"354_CR5","first-page":"27","volume":"9","author":"T Ivanovski","year":"2019","unstructured":"Ivanovski T, Miralles F. Lambert\u2013Eaton myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019;9:27\u201337.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"354_CR6","first-page":"341","volume":"7","author":"S Lindquist","year":"2011","unstructured":"Lindquist S, Stangel M. Update on treatment options for Lambert\u2013Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"354_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3111\/13696998.2012.660897","volume":"15","author":"L Harms","year":"2012","unstructured":"Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15:521\u201330.","journal-title":"J Med Econ"},{"key":"354_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893\u2013902.","journal-title":"Eur J Neurol"},{"key":"354_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86:44\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"354_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mus.26052","volume":"57","author":"DB Sanders","year":"2018","unstructured":"Sanders DB, Juel VC, Harati Y, et al. 3,4-Diaminopyridine base effectively treats the weakness of Lambert\u2013Eaton myasthenia. Muscle Nerve. 2018;57:561\u20138.","journal-title":"Muscle Nerve"},{"key":"354_CR11","first-page":"CD003279","volume":"2011","author":"M Keogh","year":"2011","unstructured":"Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert\u2013Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2011:CD003279.","journal-title":"Cochrane Database Syst Rev"},{"key":"354_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12883-021-02405-3","volume":"21","author":"N Zhang","year":"2021","unstructured":"Zhang N, Hong D, Ouyang T, et al. 3,4-Diaminopyridine treatment for Lambert\u2013Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials. BMC Neurol. 2021;21:371.","journal-title":"BMC Neurol"},{"key":"354_CR13","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1212\/WNL.0000000000008747","volume":"94","author":"AF Lipka","year":"2020","unstructured":"Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert\u2013Eaton myasthenic syndrome. Neurology. 2020;94:e511\u201320.","journal-title":"Neurology"},{"key":"354_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2710.2011.01249.x","volume":"37","author":"DM Green","year":"2012","unstructured":"Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012;37:53\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"354_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","volume":"43","author":"JA Raust","year":"2007","unstructured":"Raust JA, Goulay-Dufa\u00ff S, Le Hoang MD, Pradeau D, Guyon F, Do B. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. J Pharm Biomed Anal. 2007;43:83\u20138.","journal-title":"J Pharm Biomed Anal"},{"key":"354_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.25070","volume":"53","author":"SJ Oh","year":"2016","unstructured":"Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate (Firdapse\u00ae) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53:717\u201325.","journal-title":"Muscle Nerve"},{"key":"354_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CND.0000000000000239","volume":"20","author":"P Shieh","year":"2019","unstructured":"Shieh P, Sharma K, Kohrman B, Oh SJ. Amifampridine phosphate (Firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis. 2019;20:111\u20139.","journal-title":"J Clin Neuromuscul Dis"},{"key":"354_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","volume":"4","author":"R Mantegazza","year":"2015","unstructured":"Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS registry: baseline demographics and treatment approaches. Neurol Ther. 2015;4:105\u201324. https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-015-0034-0.pdf.","journal-title":"Neurol Ther"},{"key":"354_CR19","first-page":"E19","volume":"103","author":"ND Nguyen","year":"2019","unstructured":"Nguyen ND, Simmons DB, Bersabe AR, et al. Lambert\u2013Eaton myasthenic syndrome and Merkel cell carcinoma. Cutis. 2019;103:E19-23.","journal-title":"Cutis"},{"key":"354_CR20","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/j.bjps.2014.03.014","volume":"67","author":"RT Siau","year":"2014","unstructured":"Siau RT, Morris A, Karoo RO. Surgery results in complete cure of Lambert\u2013Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg. 2014;67:e162\u20134.","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"354_CR21","doi-asserted-by":"publisher","first-page":"e7839","DOI":"10.1097\/MD.0000000000007839","volume":"96","author":"S Portaro","year":"2017","unstructured":"Portaro S, Brizzi T, Sinicropi S, et al. Five years experience on 3,4-diaminopyridine phosphate in Lambert\u2013Eaton syndrome: case reports. Medicine (Baltimore). 2017;96:e7839.","journal-title":"Medicine (Baltimore)"},{"key":"354_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567\u201371.","journal-title":"N Engl J Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00354-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:00:04Z","timestamp":1659106804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00354-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00354-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}